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1. Introduction 
Programmed cell death (PCD) is a basic biological phenomenon that plays an important role 
during development, preservation of tissue homeostasis, and elimination of damaged cells. 
Several nomenclature systems have been proposed to classify PCD. One widely accepted 
system describes three major morphologies of programmed cell death, and classifies PCD as 
type I, apoptosis; type II, autophagy; and type III, programmed necrosis1,2.  
Type I, apoptotic cell death, acts as part of a quality-control and repair mechanism by 
elimination of unwanted, genetically damaged, or senescent cells, and as such is critically 
important for the development of organisms. Highly conserved in both plants and animals, 
it is also the cell-death mechanism best characterized at both genetic and biochemical 
levels3. Type II, autophagic cell death, is a catabolic process conserved among all eukaryotes 
from yeast to mammals4; it is a mechanism by which organelles are removed. Autophagic 
cell death is the primary degradation mechanism for long-lived proteins, and thus maintains 
quality control for proteins and organelles to enhance survival under conditions of scarcity 
or starvation. Type III, programmed necrosis, is a passive process that usually affects large 
fields of cells; in contrast, apoptosis and autophagy are controlled and energy-dependent 
and can affect individual cells or clusters of cells. Perhaps the most remarkable characteristic 
of programmed necrosis is that this death outcome appears as a distinct entity, not by 
exclusive engagement of selected effectors, but rather, by combinatorial use of the effectors 
shared with other cell-death outcomes. 
Although all three types of PCD can occur normally as a homeostatic mechanism to 
maintain the cell population in tissues, dysregulation of the delicate balance between cell life 
and PCD has tremendous pathological implications. The type of cell death that occurs 
depends on the stimulus and the cellular context, because every cell-death program is a net 
result of self-propagating signals and other signals that suppress the other cell-death 
programs2. Deficient cell death is frequently involved in early cancer development and 
tumour resistance to chemotherapy or radiotherapy5. Increasingly, evidence suggests that 
PCD is closely related to anti-cancer therapy. The cancer therapy is improved by targeting 
the PCD pathway. 
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Cervical cancer is the most prevalent malignancy of the female reproductive system. Several 
randomized controlled studies have shown survival benefits of platinum-based neoadjuvant 
chemotherapy followed by radical surgery in locally advanced cervical cancer. Survival 
benefit of neoadjuvant chemotherapy depends on high chemoresponsiveness. Considerable 
evidence indicates that platinum can kill cells through the induction of apoptosis; however, 
cancer cells, in their relentless drive to survive, hijack cell processes, resulting in resistance 
to apoptosis. This resistance underlies not only tumorigenesis, but also the inherent 
resistance of certain cancers to chemotherapy and radiotherapy. Fortunately, in addition to 
inducing apoptosis, a number of chemotherapeutic agents have been shown to induce 
nonapoptotic forms of cell death. The significance of nonapoptotic cell death in 
chemotherapy, and the mechanisms by which it is induced remain less well understood. 
Given the fact that most cancer cells have defects in the response to induction of apoptosis, it 
would be desirable if therapeutic agents could kill cancer cells resistant to apoptosis through 
alternative mechanisms. 
In this chapter, we firstly review the main features and functions of all three types of 
programmed cell death, and further elucidate the intricate relationship between apoptosis, 
autophagy and necrosis. We discuss the dual roles of autophagy in cancer and highlighted 
their relationship to tumor suppression and tumor progression. We also review several key 
autophagic mediators that play pivotal roles in autophagic signaling networks in cancer. 
Understanding the signaling pathways involved in the regulation of autophagy as well as 
the autophagy process itself represents new directions in the development of cervical cancer 
therapies. 
2. Basic features of PCD 
Programmed cell death displays several cellular phenotypes affecting various intracellular 
organelles and membranes, and the cell nucleus. For example, the well-characterized 
processes of cytoplasmic and chromatin condensation, nuclear fragmentation, membrane 
blebbing, and formation of membrane-bound apoptotic bodies are part of apoptosis. 
Autophagy involves the formation of a double-membrane vesicle which encapsulates 
cytoplasm and organelles, and fuses with lysosomes, thus resulting in the degradation of the 
vesicle contents. Programmed necrosis is characterized by the presence of swelling 
organelles followed by the appearance of “empty” spaces in the cytoplasm that merge and 
make connections with the extracellular space. The plasma membrane is fragmented, but the 
nucleus is relatively preserved6. 
2.1 Apoptosis 
The major biochemical features of apoptosis are activation of intracellular proteases 
especially caspases, and internucleosomal DNA fragmentation. Changes in several cell 
surface molecules also ensure that apoptotic cells are immediately recognized and 
phagocytized by neighboring cells in tissues, with the result that many cells can be deleted 
from tissues in relatively short time. Therefore, apoptosis results in the orderly elimination 
of cells without generating an inflammatory response7.  
The apoptosis cascade can be initiated via two major pathways, involving either activation 
of death receptors in response to ligand binding (extrinsic or death-receptor pathway), or 
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the release of proapoptotic proteins, such as cytochrome c, from mitochondria to cytosol 
(intrinsic or mitochondrial pathway)8. Some evidence has indicated that the two pathways 
are linked and that molecules involved in one pathway can influence the other9. The death 
receptor pathway is activated through the tumour necrosis factor (TNF) family of cytokine 
receptors, and has a fundamental role in maintaining tissue homeostasis, particularly in 
immune recognition. The Bcl-2 family of proteins plays a central role in controlling the 
mitochondrial pathway. Different members of the Bcl-2 family localize to the cytoplasm or 
to different subcellular compartments in healthy cells. However, upon receiving a death 
stimulus, most of these proteins carry out their functions at various intracellular 
membranes, particularly the endoplasmic reticulum (ER) and mitochondrial membranes. 
More than 20 members of this family have been identified to date in humans, including 
suppressors (Bcl-2, Bcl-XL, Mcl-1, Bfl-1/A1, Bcl-W, Bcl-G) and promoters (Bax, Bak, Bok, 
Bad, Bid, Bik, Bim, Bcl-Xs, Krk, Mtd, Nip3, Nix, Nora, Bcl-B) of apoptosis10.  
The central players in both pathways are the caspases (the cysteine-dependent, aspartate-
specific family of proteases), which also function as the executioner in apoptotic cell death11. 
Regulated at the post-translational level, caspases are synthesized as pro-caspases. Under 
stimulation of pro-apoptotic signals from different sources, pro-caspases are digested by 
protease to become active caspases. Mitochondrial dynamics contribute substantially to 
apoptotic pathways by stimulation of caspases, and by chromosomal fragmentation12,13.  
The extrinsic pathway is triggered at the cell surface through cytokine-induced death by 
receptor-mediated activation of caspase-8 or caspase-10, followed by activation of caspase-3 
and -73. The intrinsic pathway is characterized by mitochondrial dysfunction, resulting in 
cytochrome c release followed by formation of apoptosomes and subsequent activation of 
caspase-9 followed by caspases-3 and -7. Bid connects the extrinsic and intrinsic pathways. 
Cleavage of Bid by caspase-8 produces a truncated Bid fragment14 that initiates mitochondrial 
outer membrane permeabilization (MOMP) through the multidomain pro-death molecules 
Bax or Bak15. In turn, Bax/Bak translocation to mitochondria induces the release of cytochrome 
c into the cytosol and subsequent activation of the executioner caspases. 
An additional pathway involves T-cell-mediated cytotoxicity and perforin-granzyme-
dependent cell death. The perforin/granzyme pathway can induce apoptosis via either 
granzyme A or granzyme B. The granzyme A pathway activates a parallel, caspase-
independent cell-death pathway via single-stranded-DNA damage16. The extrinsic, intrinsic, 
and granzyme B pathways converge on the same terminal pathway.  
2.2 Autophagy 
Autophagy is a physiological process that plays an important role in the turnover of cellular 
proteins and other macromolecules. Moreover, it is the major catabolic route for eukaryotic 
cells to salvage essential molecules, and to maintain an adequate amino acid level to sustain 
protein synthesis during nutritional deprivation17. It is characterized by mitochondrial 
dilation, extensive intracellular membrane remodeling, and the generation of 
autophagosomes, large organelles that engulf various cellular constituents in double or 
multiple membranes. Autophagosomes subsequently fuse with lysosomes to become 
autolysosomes, where sequestered cellular components are digested18. Amino acids and 
fatty acids generated by this process can be used for protein synthesis, or can be oxidized by 
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the mitochondrial electron transport chain to produce ATP for cell survival under starvation 
conditions19. In addition to promoting cell survival, autophagy can lead to cell death.  
Based on the mechanisms used for the delivery of cargo to lysosomes, autophagy has been 
classified into three different types: macroautophagy, microautophagy, and chaperone-
mediated autophagy (CMA)20. Unlike apoptosis, which relies on the activation of caspases that 
cleave hundreds of target proteins21, autophagic cell death is caspase-independent22. Indeed, 
autophagic cell death has been demonstrated in cells with profound defects in the apoptosis 
machinery23 and in cells grown in the presence of caspase inhibitors24. Cells undergoing 
autophagic cell death look different from cells undergoing apoptosis. The characteristic 
cellular morphology of apoptosis results from caspase cleavage of cytoskeletal and other 
structural proteins21; apoptotic cells show early degradation of the cytoskeleton, but preserve 
organelles until fairly late in the process. In contrast, autophagic cell death is associated with 
accumulation of large numbers of autophagic vesicles, which degrade organelles early in the 
process, while the cytoskeleton remains intact and functional until late in the process25.  
Morphologic changes, such as chromatin condensation or membrane blebbing, may also 
occur in autophagic cell death, but there is no DNA fragmentation or formation of apoptotic 
bodies26. Over 30 ATG genes have been identified in yeast and at least 11 (ATG1, 3, 4, 5, 6, 7, 
8, 9, 10, 12 and 16) have orthologs in mammals, ATG6 is also known as BECN1 (Beclin 1) and 
ATG8 is commonly called LC3 in mammals. 
2.3 Programmed necrosis 
Accumulating evidence supports a ‘sequence’ of events that characterize necrotic cell death 
at both the phenomenological and the biochemical level, thereby reflecting a programmed 
course of events in the dying necrotic cell, and contributing to a definition of necrotic cell 
death. In addition, in some circumstances the ‘occurrence’ of necrotic cell death is also 
programmed. Type III PCD, programmed necrosis, is not due to one well-described 
signalling cascade, but is the result of interplay between several signalling pathways.  
The lack of caspase and lysosomal involvement distinguishes programmed necrosis from 
other types PCD. Programmed necrosis is characterized by early swelling of intracellular 
organelles such as mitochondria, ER, and Golgi apparatus, followed by loss of plasma 
membrane integrity. After signalling- or damage-induced lesions, necrosis can include signs 
of controlled processes such as mitochondrial dysfunction, enhanced generation of reactive 
oxygen species, ATP depletion, or proteolysis by calpains and cathepsins27. In addition, 
programmed necrosis is also typically associated with nuclear degradation that is 
accompanied by the release of nuclear factors such as high mobility group box 1 (HMGB1) 
that triggers a potent inflammatory response28,29. Recent reports describe that this 
programmed necrosis is firmly regulated and, depending on the cell-death system and/or 
PCD insult, implicates different proteins, such as TRAIL, TRADD, TRAF2, JNK1, RIP1, 
XRCC1, AIF, calpains, Bax, or Drp16,30-32. 
3. PCD-based therapeutic strategies against cancer 
Deregulation of the cellular pathways leading to PCD in mammals can cause a number of 
disease states, including neurodegenerative diseases, autoimmunity, and most prominently, 
various cancers33.  
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3.1 Apoptosis based therapeutic strategies 
Apoptosis is a major defense mechanism against malignant transformation. In fact, failures 
in normal apoptotic pathways contribute to carcinogenesis by creating a permissive 
environment for genetic instability and the accumulation of gene mutations. Tumour cells 
use a variety of molecular mechanisms to suppress apoptosis.  
Cancer cells can acquire resistance to apoptosis by the expression of anti-apoptotic proteins 
such as Bcl-2 or by the down-regulation or mutation of pro-apoptotic proteins such as Bax. The 
expression of both Bcl-2 and Bax are regulated by the product of the P53 tumour suppressor 
gene, a transcription factor that regulates the cell cycle, and which mutation occurs in over half 
of all human tumors. Among the remaining tumors, although they may process a wild-type 
P53, the pathways of P53-induced cell-cycle arrest and apoptosis are deficient. Therefore, P53 
serves as a unique molecular target for cancer therapy. PRIMA-1 (P53 reactivation and 
induction of massive apoptosis) is the second class of compounds reported to have the 
capability of restoring tumor-suppressor function to mutant P53, and it does not appear to 
have an effect on wild-type P53. This makes PRIMA-1 unique among all the 
chemotherapeutics currently used in the clinic34. In addition, p73 belongs to a small but 
important family of p53-related proteins (p53, p63, p73). The Trp73 gene contains two 
promoters that drive the expression of two major groups of p73 isoforms with opposing 
cellular actions: The TAp73 isoforms contain the p73 transactivation domain (TA) and exhibit 
proapoptotic activities, whereas the ∆Np73 isoforms lacking the N-terminal TA domain are 
anti-apoptotic. It has been proposed that a loss of p73 function might lead to tumorigenesis35, 
and that TAp73 down-regulation may be coupled with ∆Np73 up-regulation in some tumors36. 
Therefore, ∆Np73 is a marker of poor prognosis in many cancers, and pharmacological 
attempts are being made to inhibit ∆Np73 expression. Another mechanism of apoptosis-
suppression in cancer involves evasion of immune surveillance37. 
An agent that can selectively induce cell death in transformed cells without affecting normal 
cells would be an ideal anti-cancer chemotherapeutic agent. In fact, the molecular mechanisms 
that control and execute apoptotic cell death in cancer growth and resistance have been 
coming into focus and are enabling a new era of drug development for cancer treatment38.  
A variety of experimental approaches have been explored in the development of anti-cancer 
compounds that block Bcl-2 function. These include the use of antisense oligonucleotides to 
Bcl-2 that target gene expression at the mRNA level, peptides that mimic BH3 domains and 
bind to the pocket of Bcl-2 where pro-apoptotic BH3-only proteins would normally bind, and 
small molecule inhibitors of Bcl-2 function. The first attempt to introduce an agent that 
specifically targets Bcl-2 was made by Genta with their antisense DNA agent, oblimersen. On 
the basis of preclinical studies that found that antisense inhibition of Bcl2 levels could induce 
death in cancer cell lines, they designed a phosphorothioate DNA molecule complementary to 
Bcl2. More recently, in a study of chronic lymphocytic leukaemia (CLL), an improvement in 
response rate was observed in relapsed CLL patients when oblimersen was added to 
fludarabine and cyclophosphamide39. Albeit limited and not as diverse, some studies have also 
designed gene therapy approaches to enhance the activities of pro-death Bcl-2 proteins. 
Adenoviral vectors expressing these genes have recently been constructed with the goal of 
delivering them into cancer cells. Adenovirus-mediated overexpression of Bax, Bcl-Xs, Bik and 
others has been a successful strategy for killing various cancer cell lines40,41. In addition, Cancer 
cells produce higher levels of ROS (reactive oxygen species) than normal cells due to increased 
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metabolic stress and proliferative rate.42-44 Excessive ROS production may increase the 
permeability of lysosomal membranes, leading to release of lysosomal proteases, which 
further contribute to mitochondrial membrane impairment11 and cancer progression43-45. It has 
been reported42 that increasing ROS generation selectively sensitizes oncogenically 
transformed cells to β-phenylethyl-isothiocyanate-induced cell death, suggesting that 
increasing ROS generation in cancer cells could be a strategy for cancer therapy.  
The selective activation of caspases might be a valuable strategy for combating cancer where 
pathogensis is related to insufficient cell death. Several strategies that trigger caspase 
activation have been developed, and several drugs that act in this way are currently being 
tested in preclinical trials. Therapeutic strategies have included adenovirus-mediated 
expression of caspases-3, -6, -8 and -9, which has resulted in both in vivo and in vitro anti-
tumourogenic activities46. In addition, adenoviral gene therapy approaches have also been 
used in the delivery of caspase constructs that can be activated on demand by the addition 
of a compound readily able to penetrate the cell membrane. The strategy relies on the fusion 
of caspases to one or chimeric “death switches”, which can be activated by chemical 
inducers of dimerization specific for a given construct47. There is considerable evidence that 
cysteine cathepsins play an important role in executing the apoptotic program in several 
tumour cell lines induced by death ligands such as TNF-,49 or TNF-related apoptosis 
inducing ligand (TRAIL)50. In the last few years, an apoptosis inducing agent, TRAIL, that 
was shown to target cancer cells specifically without damaging normal cells and tissues has 
received special interest in cancer therapy. Several groups recently discovered a cathepsin-
mediated proteolytic event in the apoptotic pathway triggered by TRAIL. First, the 
inhibition of TRAIL-induced apoptosis was observed upon treatment of oral squamous 
carcinoma cells with cathepsin inhibitors51. Subsequently, the pathway for apoptosis 
induction through Bid activation was confirmed in several other tumour cell lines50,52,53.  
3.2 Autophagy based therapeutic strategies 
In tumour cells in which the quality control mechanisms of both apoptosis and autophagy 
are disabled, failure to maintain energy homeostasis accelerates the generation of damaged 
cells54. This failure of protein/organelle quality control to curtail the accumulation of 
damaged proteins and organelles through autophagy may have a broad impact on cellular 
functions, leading either directly or indirectly to genome damage that promotes 
tumourigenesis. This may mean that autophagy is one of the mechanisms that contribute to 
the breakdown of cell growth control in cancer 55.  
In contrast to the potential cancer-promoting effect of autophagy, numerous observations 
have demonstrated that loss-of-function mutations in the autophagy pathway are associated 
with tumour progression56,57. Furthermore, constitutive activation of the PI3K pathway is 
one of the most common events in human cancer58, and the downstream kinase mTOR 
restricts autophagy induction in response to starvation59. Although many human cancers 
exhibit mutations in pro-autophagy genes, and several tumour suppressor genes (e.g., 
DAPK, PTEN, and TP53) can stimulate autophagy60, the molecular mechanism through 
which autophagy inhibits oncogenesis is currently unclear.  
Therapeutically induced autophagic cell death is another method for tumour-cell killing. 
Especially in apoptosis-defective cells, autophagy is often induced by cytotoxic drugs; the 
excessive cellular damage and attempt to remediate that damage through progressive 
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autophagy can promote autophagic cell death23. Inhibition of autophagy is important in 
cancer therapy. The process of cancer metastasis necessarily requires that tumour cells 
survive in isolation from the primary tumour, without its nutrient support system. Thus, 
early metastases may be particularly susceptible to inhibition of autophagy.  
Potential synergy with proteasome inhibitors is another reason for the use of autophagy 
inhibitors. The ubiquitin-mediated proteasome protein degradation pathway is functionally 
compensatory with protein turnover by lysosomal degradation through the autophagy 
pathway61,62. Therefore, protein degradation that is mediated by autophagy and 
proteasomes may be lethally exclusive to tumour cells with a high metabolic rate, or with 
increased susceptibility to the production of unfolded proteins. The ubiquitin-proteasome 
pathway is an intracellular proteolytic system which regulates the degradation of a broad 
spectrum of intracellular proteins, including diverse regulators of cell proliferation or 
apoptosis. Both bortezomid- and lenalidomide-based therapies are especially active, with 
bortezomib in particular being shown to provide a platform for combination, which is able 
to overcome resistance in this setting. Bortezomib，a first-in-class proteasome 
inhibitor，represents the prototypic member of a class of peptide boronate proteasome 
inhibitors of 26S proteasome activity, and has been approved by the US Food and Drug 
Administration, shows efficacy in treating multiple myeloma63.  
3.3 Programmed necrosis based therapeutic strategies 
Type III PCD, programmed necrosis, is usually defined in a negative fashion, as a type of 
cell demise that involves rupture of the plasma membrane without the hallmarks of 
apoptosis and without massive autophagic vacuolization. Necrosis lacks specific 
biochemical markers apart from the presence of plasma membrane permeabilization, and 
can be detected only by electron microscopy. Necrosis is considered to be harmful because it 
is often associated with pathological cell loss and because of the ability of necrotic cells to 
promote local inflammation that may support tumour growth64. However, necrotic cell 
death is induced in cancer cells by the therapeutic administration of alkylating DNA 
damaging agents65 and photosensitizing molecules that preferentially accumulate in tumour 
cells and generate ROS following excitation with light from various spectra66,67. 
4. The relationship of PCD to cervical cancer therapy 
The ultimate goal of anticancer therapy is to kill cancer cells quickly and effectively. Over 
the past two decades, it has become clear that cell death, in both malignant and non-
malignant cells, can be an active, regulated program. Thus, elucidation of the programmed 
cell-death pathways will provide new insight into tumour biology, revealing novel 
strategies for combating cancer. Tumour cells can only persist if they ignore the requirement 
for senescence that is imposed on all cells of organisms. Failure to execute PCD is usually a 
reflection of defective or absent molecular components of the cell-death machinery. Cervical 
cancer is second only to breast cancer in women as the most common of gynecologic 
malignancies, and it remains one of the most important causes of mortality in women 
worldwide. In recent years, cervical cancer has been affecting younger women. Because 
radiation therapy will negatively affect ovarian function in women of reproductive age, 
chemotherapy for cervical cancer has been receiving increased attention from clinicians. 
Although platinum-based neoadjuvant chemotherapy is an attractive option for 
www.intechopen.com
 
Topics on Cervical Cancer with an Advocacy for Prevention 
 
260 
chemotherapy given prior to surgery, and can reduce tumor size and lead to improvement 
in overall survival, cancer cells often harbor mutations that confer resistance to apoptosis, 
suggesting the need for other therapeutic approaches that would exploit non-apoptotic cell 
modes of death or enhance cell apoptosis for cervical cancer therapy. 
4.1 Apoptosis autophagy and cervical cancer therapy 
The mechanism of tumour cell killing by an anti-cancer agent determines the way that the 
agent selects for resistance to the therapy. A drug that induces apoptosis might provide 
quite different selective pressures on the tumour cell compared with a drug that induces 
autophagic cell death. Thus, drugs with different mechanisms of action would be expected 
to have different levels of efficacy against a particular tumour68. On the other hand, the close 
connections between the apoptosis machinery and other PCD machinery under 
investigation would be expected to result in simultaneous activation of these PCD processes.  
When treating cancer, we often use drugs that cause severe damage to the cell. Regulation of 
PCD using caspase activators/inhibitors can constitute a treatment for cancer or for other 
PCD defective/excessive diseases69. Blockage of caspase activation causes degradation of 
catalase; the resultant increase in ROS generation leads to cell death. Degradation of catalase 
is also mediated by autophagy, thus suggesting a role for autophagy in caspase-
independent cell death70. So, when cancer cells are treated, the induction of autophagy, and 
the interactions between autophagy and apoptosis could have profound effects on the 
outcome for the tumour cell.  
Some connections occur upstream of the apoptotic and autophagic machinery where 
signalling pathways regulate both processes. For example, the autophagy gene beclin1 is part 
of a Type III PI3 kinase complex that is required for the formation of the autophagic vesicle, 
and that interacts with Bcl-2. A study found that the protein level of Beclin1 is lower in cervical 
cancer tissues than in normal tissues, and is closely related to pelvic lymph node metastases 
and histologic tumor grade71. Overexpression of Beclin1 in human cervical cancer SiHa and 
HeLa cell lines may induce the massive cells from to autophagy and inhibit tumor cell 
growth72,73. Another experiment indicates that beclin1 may be the critical molecular switch that 
plays an important role in fine tuning the autophagy and apoptosis through caspase-9 in 
cervical cancer cells72. Beclin1 also interacts with the other major anti-apoptotic Bcl family 
protein (Bcl-xL). It has been shown that autophagy can be regulated by this interaction. In 
addition to inhibiting apoptosis by binding to and interfering with the action of the pro-
apoptotic proteins Bax and Bak, Bcl-2/Bcl-xL also inhibits autophagy by binding with beclin1. 
This latter interaction is particularly important in the regulation of starvation-induced 
autophagy74. Bcl-2 can inhibit autophagy not only by interacting with beclin1, but also by 
blocking calcium release from the ER75. Conversely, DRAM (damage-regulated autophagy 
modulator), a well known component of the autophagic machinery, is essential also for p53-
mediated apoptosis76. Similarly, activation of the PI3 kinase/Akt pathway, a well-known way 
to inhibit apoptosis, also inhibits autophagy77. Thus important signalling pathways apparently 
simultaneously increase and decrease both autophagy and apoptosis. In our laboratory, we 
achieved stable transfectants expressing Beclin1 in cervical cancer CaSki cells, and observed 
that Beclin1 induced cell arrest in the G0/G1 phase. We then selected several drugs that can 
induce apoptosis to cancer cells by various mechanisms, including a anti-microtubule agent 
(paclitaxel), a platinum agent (cisplatin), an anti-metabolite (5-fluorouracil), and an 
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anthracycline (epirubicin), to detect the role of Beclin1 in chemosensitivity. We found that 
Beclin1 overexpression in CaSki cells reduced cell survival following exposure to all four anti-
cancer drugs. However, down-regulation of endogenous Beclin1 by siRNA in the CaSki cells 
did not lead to obvious resistance to the anti-cancer drugs. Taken together, these data provide 
evidence that Beclin1 is associated with chemosensitivity and the level of expression causes 
changes in response to chemotherapeutic drugs in cervical cancer, at least in vitro, despite the 
distinct damage mechanisms to cancer cells of these drugs78, 79. 
It has been suggested the mitochondrion may be the central organelle that integrates apoptosis 
and autophagy80. A positive feedback mechanism can be elicited by the activation and 
maturation of pre-apoptotic factors from autophagic processes in mitochondria, and lead to 
cell destruction through apoptotic and autophagic mechanisms. Autophagy can stop cells 
from undergoing apoptosis by sequestration of damaged mitochondria81. Moreover, some of 
the signals that are involved in apoptosis may also be involved in autophagy. For example, in 
both apoptosis and autophagy, there is the coordinated regulation of Akt and p70S6 kinase. 
Other proteins that may be part of the network connecting the two types of cell death include 
DAPK, Beclin1, BNIP3, HSpin1, or protymosin-α82. In our previous study73, we found that both 
autophagy and apoptosis were activated during carboplatin-induced death of cervical cancer 
cells. Beclin1 may act as an orchestrator, integrating apoptotic and autophagic activities. 
Another study demonstrated that autophagy and apoptosis contribute to etoposide-induced 
CaSki cervical cancer cell death, and autophagy may be the predominant mechanism of 
etoposide-induced cell death83. In addition, multiple death stimuli converge on mitochondria 
to provoke MOMP and release of apoptogenic factors such as cytochrome c, Smac/Diablo, 
Omi/HtrA2, Endonuclease G (Endo G), or AIF. Once released into the cytosol, these proteins 
initiate apoptosis, autophagy, or programmed necrosis30,31,84.  
4.2 Programmed necrosis and cervical cancer therapy 
Increasing evidence indicates that programmed necrosis can occur as a result of the 
activation of specific signal transduction cascades, and subsequently can be actualized only 
on inhibition of apoptosis and/or autophagy. Thus, it might be therapeutically desirable to 
trigger necrotic cell death in tumour cells that might have been selected to resist apoptotic or 
autophagic cell death.  
Studies suggest that cell death that usually manifests with an apoptotic morphology can be 
shifted to a more necrotic morphology when caspase activation is prevented by 
pharmacological inhibitors, or by the elimination of essential caspase activators such as 
Apaf-185. In some situations, caspase inhibition can even sensitize cells to the induction of 
necrosis, thereby reducing the dose of TNFa required to kill some cell lines86. A study found 
that heat treatment can induce cervical cancer CaSki cell apoptosis and necrosis87. Of the 
thermal conditions, 45˚C exhibited the best induction of apoptosis, while 47˚C induced 
direct fierce necrosis. This was further demonstrated by examining the expression level of 
several key apoptosis-related genes: caspase-3, Smac and Survivin. During apoptosis, 
caspase-3 and Smac levels were up-regulated, whereas anti-apoptotic Survivin was down-
regulated, enhancing programmed cell death. Similarly, inhibition of autophagy by 
transfection with constitutively active Akt protein kinase, or knockout of one of the alleles 
encoding the Beclin1 protein also determines a shift from type II (autophagy) to type III 
(programmed necrosis) cell death56. Another study88 also suggests that necrotic cell death 
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induces an immune response against the dying cell through the release of pro-inflammatory 
cytokines, which help to initiate the repair of damaged tissue. In this way, programmed 
necrosis differs fundamentally from apoptosis. Death by programmed necrosis is passive, 
causes cellular contents to be released into the extracellular space, and often causes 
inflammation. In addition, oxidative-stress-induced cell death is not completely blocked by 
inhibiting either apoptosis or autophagy. Indeed, in the hypoxic region of a tumour, where 
both apoptosis and autophagy are inhibited, increased necrosis with infiltration of 
macrophages and production of cytokines and chemokines has been observed in mouse 
models56. What specifically triggers necrosis is unknown, but ATP production insufficient to 
maintain plasma-membrane integrity results in metabolic catastrophe, making cell lysis 
highly probable89. Thus, it is also reasonable to assume that cells under oxidative stress 
could undergo cell death through multiple pathways including necrosis.  
5. Summary 
PCD is a genetically regulated process that allows for the maintenance of tissue homeostasis 
and cell numbers, and provides protection against damaged or infected cells that threaten 
this balance. It is becoming increasingly clear that PCD is involved in cancer formation and 
survival; the process of PCD responds to several forms of cancer treatments. Elimination of 
cancer cells might occur not only via apoptosis, but could also be mediated by other forms 
of cell death such as autophagy and programmed necrosis. In recent years, the PCD-based 
pharmacological therapies were mainly focused on apoptosis and the main regulators of this 
PCD pathway, the caspase family of cysteine proteases. Drug resistance limits the 
effectiveness of existing medical treatments, and is still a major challenge in the current 
research on PCD. To better understand the pathology and the potential therapeutic 
strategies for human cancer that are characterized by enhanced cell death, it is crucial to 
elucidate the death mechanism(s) directly involved in each cancer. Treatment should 
depend on the actual mechanism of cell death that plays a role in disease onset. Modulation 
of the autophagic pathway may be a novel way of sensitizing cervical cancer cells to anti-
cancer drug therapy90, and further studies of autophagy, apoptosis and necrosis may 
provide new insights into the mechanisms accommodating or contributing to PCD, thereby 
unveiling new strategies for cervical cancer therapy. 
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